abstract: OBJECTIVE: This study longitudinally profiled @entity2 and @entity3 of daughters of @entity1 with @entity0 and examined the mother* s survival status, the daughter* s age at the time of mother* s diagnosis, and the style of family communication about @entity0 as moderators of change in symptomatology across @entity1 *  first 3 appointments at the University of California, Los Angeles Revlon Breast Center High Risk Clinic. METHODS: We evaluated the effects of hypothesized predictors on change in @entity2 and @entity3 , 3 (symptomatology at first, second, and third clinic visits) * 2 (mother survived or died) * 2 (<20 or >= 20y old at diagnosis) * 2 (open or closed family communication) repeated-measures analyses of variance were employed. RESULTS: There was a main effect for time of diagnosis on state @entity2 , demonstrating a significant reduction in @entity2 across clinic visits overall (p < 0.001). There were also significant 3-way interactions. For state @entity2 , mother* s survival status moderated the time of diagnosis * age at diagnosis and time of diagnosis * family communication interaction effects. For daughters whose mothers died, decreased @entity2 was observed in those who were younger at the time of diagnosis (p = 0.001). For daughters whose mothers survived, @entity2 was decreased for those with closed family communication styles (p = 0.001). The time of diagnosis * mother* s survival * age at diagnosis interaction was also significant for @entity3 (p = 0.001). Among daughters whose mothers died, those who were younger showed decreases in symptoms (p = 0.004). CONCLUSION: These daughters appeared to benefit from the high-risk program as demonstrated by decreased symptomatology, particularly daughters whose mothers died who were younger at the time of diagnosis.

title: Evolution of Emotional Symptoms Over Time Among Daughters of @entity1 With XXXX .

answer: @entity0


abstract: OBJECTIVE: This study longitudinally profiled @entity2 and @entity3 of daughters of @entity1 with @entity0 and examined the mother* s survival status, the daughter* s age at the time of mother* s diagnosis, and the style of family communication about @entity0 as moderators of change in symptomatology across @entity1 *  first 3 appointments at the University of California, Los Angeles Revlon Breast Center High Risk Clinic. METHODS: We evaluated the effects of hypothesized predictors on change in @entity2 and @entity3 , 3 (symptomatology at first, second, and third clinic visits) * 2 (mother survived or died) * 2 (<20 or >= 20y old at diagnosis) * 2 (open or closed family communication) repeated-measures analyses of variance were employed. RESULTS: There was a main effect for time of diagnosis on state @entity2 , demonstrating a significant reduction in @entity2 across clinic visits overall (p < 0.001). There were also significant 3-way interactions. For state @entity2 , mother* s survival status moderated the time of diagnosis * age at diagnosis and time of diagnosis * family communication interaction effects. For daughters whose mothers died, decreased @entity2 was observed in those who were younger at the time of diagnosis (p = 0.001). For daughters whose mothers survived, @entity2 was decreased for those with closed family communication styles (p = 0.001). The time of diagnosis * mother* s survival * age at diagnosis interaction was also significant for @entity3 (p = 0.001). Among daughters whose mothers died, those who were younger showed decreases in symptoms (p = 0.004). CONCLUSION: These daughters appeared to benefit from the high-risk program as demonstrated by decreased symptomatology, particularly daughters whose mothers died who were younger at the time of diagnosis.

title: Evolution of Emotional Symptoms Over Time Among Daughters of XXXX With @entity0 .

answer: @entity1


abstract: UNASSIGNED: The purpose of the present study was to assess the effect of resveratrol ( @entity1 ) pretreatment on CYP3A4 enzyme activity and pharmacokinetics of carbamazepine (CBZ) in healthy @entity0 volunteers. The open-label, two period, sequential study was conducted in 12 healthy @entity0 volunteers. A single dose of @entity1 500   mg was administered once daily for 10   days during treatment phase. A single dose of CBZ 200   mg was administered during control and after treatment phases under fasting conditions. The blood samples were collected after CBZ dosing at predetermined time intervals and analyzed by LC-MS/MS. In comparison with the control, @entity1 pretreatment significantly enhanced maximum plasma concentration (Cmax ), area under the curve (AUC), and half life (t1/2 ) and significantly decreased apparent oral clearance (CL/F) and apparent volume of distribution (Vd/F), while there was no significant change observed in time to reach maximum concentration (tmax ) and elimination rate constant (kel ) of CBZ. Furthermore, @entity1 pretreatment significantly decreased metabolite to parent (CBZE/CBZ) ratios of Cmax and AUC and significantly increased CBZE/CBZ ratios of CL/F and Vd/F, indicating the reduced formation of CBZE to CBZ. The results suggest that the altered CYP3A4 enzyme activity and pharmacokinetics of CBZ might be attributed to @entity1 -mediated inhibition of CYP3A4 enzyme. Thus, there is a potential pharmacokinetic interaction between @entity1 and CBZ including other CYP3A4 substrates. Copyright    2015 John Wiley _ Sons, Ltd.

title: Effect of Resveratrol on the Pharmacokinetics of Carbamazepine in Healthy XXXX Volunteers.

answer: @entity0


abstract: PURPOSE: Most pre-clinical @entity1 studies address the acute phase after injury, with less attention to long-term effects of injury, treatment, and experimental testing itself. We addressed these questions: 1) Will functional deficits persist up to 8 weeks following transient @entity1 in older animals? 2) Will functional deficits resolve spontaneously, with time and/or repeated behavioral testing? METHODS: Male @entity0 (12 months) were pre-trained on behavioral tasks to provide baseline data and then underwent transient middle @entity3 (tMCAO) or sham surgery. We measured motor, sensory, cognitive and @entity2 over 8 weeks, and the extent of hemispheric @entity4 . One cohort underwent behavioral testing once at 8 weeks post- @entity1 (LT); a second cohort (RLT) was tested at 3, 6 and 8 weeks post- @entity1 . RESULTS: Significant deficits were exhibited in all functional outcomes in both cohorts after 8 weeks. We observed some recovery in some behavioral parameters in both cohorts at 8 weeks. CONCLUSIONS: Deficits persist for at least 8 weeks after tMCAO. The greater spontaneous recovery seen in the RLT groups suggest that repeated testing did reduce the severity of these @entity1 . These findings have implications for designing future studies of agents to induce long-term functional recovery following @entity1 .

title: Long-term behavioral deficits and recovery after transient ischemia in middle-aged XXXX : Effects of behavioral testing.

answer: @entity0


abstract: The efficacy and safety of ceftibuten (9 mg/kg daily for 10 days) were compared with those of @entity1 / @entity3 ( @entity5 40 mg/kg/day given every 8 hours for 10 days) in the empiric treatment of @entity2 media in @entity0 . This was a multicenter, investigator-blinded study with 1:1 randomization. Overall clinical response and signs and symptoms of @entity4 were collected prospectively pretreatment, 3 to 5 days during treatment, 1 to 3 days post-treatment and at 2- to 4-week follow-up. In addition to spontaneous reports of other adverse events, gastrointestinal adverse events were prospectively elicited at each visit. Two hundred ninety-six @entity0 (146 ceftibuten and 150 @entity1 / @entity3 ) were treated with at least 1 dose of study medication. Compliance with dosing was assessable with weight of drug consumed in 127 @entity0 in each treatment group. Five percent (6 of 127) of ceftibuten @entity0 and 11% (14 of 127) of @entity1 / @entity3 @entity0 received < 80% of prescribed drug (P = 0.10) and were therefore not valid. Two hundred twenty-two @entity0 (121 ceftibuten and 101 @entity1 / @entity3 ) received a minimum of 80% of prescribed medication and were compliant with the protocol. Ceftibuten and @entity1 / @entity3 groups were comparable both for demographic variables and for baseline signs and symptoms.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Multicenter controlled trial comparing ceftibuten with @entity1 / @entity3 in the empiric treatment of XXXX media. Members of the Ceftibuten Otitis Media United States Study Group.

answer: @entity2


abstract: The efficacy and safety of ceftibuten (9 mg/kg daily for 10 days) were compared with those of @entity1 / @entity3 ( @entity5 40 mg/kg/day given every 8 hours for 10 days) in the empiric treatment of @entity2 media in @entity0 . This was a multicenter, investigator-blinded study with 1:1 randomization. Overall clinical response and signs and symptoms of @entity4 were collected prospectively pretreatment, 3 to 5 days during treatment, 1 to 3 days post-treatment and at 2- to 4-week follow-up. In addition to spontaneous reports of other adverse events, gastrointestinal adverse events were prospectively elicited at each visit. Two hundred ninety-six @entity0 (146 ceftibuten and 150 @entity1 / @entity3 ) were treated with at least 1 dose of study medication. Compliance with dosing was assessable with weight of drug consumed in 127 @entity0 in each treatment group. Five percent (6 of 127) of ceftibuten @entity0 and 11% (14 of 127) of @entity1 / @entity3 @entity0 received < 80% of prescribed drug (P = 0.10) and were therefore not valid. Two hundred twenty-two @entity0 (121 ceftibuten and 101 @entity1 / @entity3 ) received a minimum of 80% of prescribed medication and were compliant with the protocol. Ceftibuten and @entity1 / @entity3 groups were comparable both for demographic variables and for baseline signs and symptoms.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Multicenter controlled trial comparing ceftibuten with @entity1 / XXXX in the empiric treatment of @entity2 media. Members of the Ceftibuten Otitis Media United States Study Group.

answer: @entity3


abstract: The efficacy and safety of ceftibuten (9 mg/kg daily for 10 days) were compared with those of @entity1 / @entity3 ( @entity5 40 mg/kg/day given every 8 hours for 10 days) in the empiric treatment of @entity2 media in @entity0 . This was a multicenter, investigator-blinded study with 1:1 randomization. Overall clinical response and signs and symptoms of @entity4 were collected prospectively pretreatment, 3 to 5 days during treatment, 1 to 3 days post-treatment and at 2- to 4-week follow-up. In addition to spontaneous reports of other adverse events, gastrointestinal adverse events were prospectively elicited at each visit. Two hundred ninety-six @entity0 (146 ceftibuten and 150 @entity1 / @entity3 ) were treated with at least 1 dose of study medication. Compliance with dosing was assessable with weight of drug consumed in 127 @entity0 in each treatment group. Five percent (6 of 127) of ceftibuten @entity0 and 11% (14 of 127) of @entity1 / @entity3 @entity0 received < 80% of prescribed drug (P = 0.10) and were therefore not valid. Two hundred twenty-two @entity0 (121 ceftibuten and 101 @entity1 / @entity3 ) received a minimum of 80% of prescribed medication and were compliant with the protocol. Ceftibuten and @entity1 / @entity3 groups were comparable both for demographic variables and for baseline signs and symptoms.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Multicenter controlled trial comparing ceftibuten with XXXX / @entity3 in the empiric treatment of @entity2 media. Members of the Ceftibuten Otitis Media United States Study Group.

answer: @entity1


abstract: BACKGROUND: Spinal anaesthesia is the preferred technique to fix @entity2 of the femur. @entity1 does not allow ideal positioning for this procedure. Intravenous fentanyl and @entity4 are commonly used techniques to reduce the @entity1 during position for spinal anaesthesia however; results are conflicting regarding superiority of @entity4 over intravenous fentanyl. AIMS: We conducted this study to compare the analgesic effect provided by @entity4 (FNB) and intra- venous (IV) fentanyl prior to positioning for central @entity3 in @entity0 undergoing surgery for femur @entity2 . @entity0 AND METHODS: In this randomized prospective study 60 @entity0 scheduled for @entity2 under spinal were included. @entity0 were distributed in two groups through computer generated random numbers table; Femoral @entity3 group (FNB) and Intravenous fentanyl group (FENT). In FNB group @entity0 received FNB guided by a peripheral nerve stimulator (Stimuplex; B Braun, Melsungen, AG) 5 minutes prior to positioning. 20mL, 1.5% lidocaine with adrenaline (1:200,000) was injected incrementally after a negative aspiration test. @entity0 in the fentanyl group received injection fentanyl 1  g/kg IV 5 mins prior to positioning. Spinal block was performed and @entity1 scores before and during positioning were recorded. Statistical analysis was done with Sigmaplot version-10 computer software. Student t-test was applied to compare the means and P < 0.05 was taken as significant. RESULTS: VAS during positioning in group FNB: 0.57    0.31 versus FENT 2.53    1.61 (P = 0.0020). Time to perform spinal anesthesia in group FNB: 15.33    1.64 min versus FENT 19.56    3.09 min (P = 0.000049). Quality of @entity0 positioning for spinal anesthesia in group FNB 2.67   0.606 versus FENT 1.967    0.85 (P = 0.000027). @entity0 acceptance was less in group FENT (P = 0.000031). CONCLUSION: Femoral @entity3 provides better analgesia, @entity0 satisfaction and satisfactory positioning than IV fentanyl for position during spinal anaesthesia in @entity0 of @entity2 femur.

title: Comparative evaluation of XXXX and intravenous fentanyl for positioning during spinal anaesthesia in surgery of femur @entity2 .

answer: @entity4


abstract: BACKGROUND: Spinal anaesthesia is the preferred technique to fix @entity2 of the femur. @entity1 does not allow ideal positioning for this procedure. Intravenous fentanyl and @entity4 are commonly used techniques to reduce the @entity1 during position for spinal anaesthesia however; results are conflicting regarding superiority of @entity4 over intravenous fentanyl. AIMS: We conducted this study to compare the analgesic effect provided by @entity4 (FNB) and intra- venous (IV) fentanyl prior to positioning for central @entity3 in @entity0 undergoing surgery for femur @entity2 . @entity0 AND METHODS: In this randomized prospective study 60 @entity0 scheduled for @entity2 under spinal were included. @entity0 were distributed in two groups through computer generated random numbers table; Femoral @entity3 group (FNB) and Intravenous fentanyl group (FENT). In FNB group @entity0 received FNB guided by a peripheral nerve stimulator (Stimuplex; B Braun, Melsungen, AG) 5 minutes prior to positioning. 20mL, 1.5% lidocaine with adrenaline (1:200,000) was injected incrementally after a negative aspiration test. @entity0 in the fentanyl group received injection fentanyl 1  g/kg IV 5 mins prior to positioning. Spinal block was performed and @entity1 scores before and during positioning were recorded. Statistical analysis was done with Sigmaplot version-10 computer software. Student t-test was applied to compare the means and P < 0.05 was taken as significant. RESULTS: VAS during positioning in group FNB: 0.57    0.31 versus FENT 2.53    1.61 (P = 0.0020). Time to perform spinal anesthesia in group FNB: 15.33    1.64 min versus FENT 19.56    3.09 min (P = 0.000049). Quality of @entity0 positioning for spinal anesthesia in group FNB 2.67   0.606 versus FENT 1.967    0.85 (P = 0.000027). @entity0 acceptance was less in group FENT (P = 0.000031). CONCLUSION: Femoral @entity3 provides better analgesia, @entity0 satisfaction and satisfactory positioning than IV fentanyl for position during spinal anaesthesia in @entity0 of @entity2 femur.

title: Comparative evaluation of @entity4 and intravenous fentanyl for positioning during spinal anaesthesia in surgery of femur XXXX .

answer: @entity2


abstract: To monitor the compliance of @entity0 taking @entity3 as replacement therapy for @entity1 , the authors measured serum @entity4 ( @entity4 ), free @entity3 index (FT4I), and free @entity2 index (FT3I) in @entity0 attending the endocrine clinic. During a 6-month period, there were 159 visits by 132 @entity0 with @entity1 . Five of the 132 @entity0 had @entity4 levels greater than 12 microU/ml (normal, 0.3-5.7 microU/ml), with FT3I greater than 85 (normal, 70-160) and FT4I greater than 7 (normal, 4.2-11). Four others had @entity4 greater than 6 microU/ml with normal FT3I and normal FT4I. These nine @entity0 had normal thyroid tests documented on replacement therapy in the past. Five of the nine admitted to discontinuing their medicine for more than 1 week or taking it erratically. Two untreated @entity1 @entity0 had daily thyroid function tests after they were started on full replacement doses of @entity3 . Both achieved FT4I greater than 4.2 by day 8 and FT3I greater than or equal to 70 by day 18, but serum @entity4 concentration did not fall consistently below 20 microU/ml until day 23 in one @entity0 and day 21 in the other and did not fall to the normal range by discharge at day 37 in one @entity0 or day 42 in the other. Thus, although treatment with @entity3 will normalize serum T4 and T3 concentrations within 3 weeks, normalization of serum @entity4 may take several more weeks. This prospective study in a large out- @entity0 clinic shows that 4% of @entity0 with treated @entity1 may have elevation of serum @entity4 to more than twice the upper limit of normal, while serum T4 and T3 are clearly normal.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Serum XXXX concentration as an aid to monitoring compliance with thyroid hormone therapy in @entity1 .

answer: @entity4


abstract: To monitor the compliance of @entity0 taking @entity3 as replacement therapy for @entity1 , the authors measured serum @entity4 ( @entity4 ), free @entity3 index (FT4I), and free @entity2 index (FT3I) in @entity0 attending the endocrine clinic. During a 6-month period, there were 159 visits by 132 @entity0 with @entity1 . Five of the 132 @entity0 had @entity4 levels greater than 12 microU/ml (normal, 0.3-5.7 microU/ml), with FT3I greater than 85 (normal, 70-160) and FT4I greater than 7 (normal, 4.2-11). Four others had @entity4 greater than 6 microU/ml with normal FT3I and normal FT4I. These nine @entity0 had normal thyroid tests documented on replacement therapy in the past. Five of the nine admitted to discontinuing their medicine for more than 1 week or taking it erratically. Two untreated @entity1 @entity0 had daily thyroid function tests after they were started on full replacement doses of @entity3 . Both achieved FT4I greater than 4.2 by day 8 and FT3I greater than or equal to 70 by day 18, but serum @entity4 concentration did not fall consistently below 20 microU/ml until day 23 in one @entity0 and day 21 in the other and did not fall to the normal range by discharge at day 37 in one @entity0 or day 42 in the other. Thus, although treatment with @entity3 will normalize serum T4 and T3 concentrations within 3 weeks, normalization of serum @entity4 may take several more weeks. This prospective study in a large out- @entity0 clinic shows that 4% of @entity0 with treated @entity1 may have elevation of serum @entity4 to more than twice the upper limit of normal, while serum T4 and T3 are clearly normal.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Serum @entity4 concentration as an aid to monitoring compliance with thyroid hormone therapy in XXXX .

answer: @entity1


abstract: BACKGROUND: In Ayurveda, asafetida is introduced as a valuable remedy for @entity9 , @entity8 , @entity4 , @entity7 , @entity2 and @entity5 in @entity0 and also considered as an aphrodisiac agent. Presently, @entity3 is common in most countries of the world and is a serious health problem in the world. Some plant medicines and natural products have a new candidate for treatment of @entity3 . OBJECTIVE: This study was designed to evaluate Ferula assa-foetida oleo gum resin (asafetida) on mortality and morbidity @entity6 in vitro. MATERIALS AND METHODS: Mostigotes were isolated from @entity1 spleens and then transformed to promastigotes in Novy-Nicolle-Mac Neal (NNN medium supplemented with penicillin (100 U/ml), streptomycin (100  g/ml) and 20% heat-inactivated fetal calf serum (FCS) at 25  C. A fixed initial density of the parasites was transferred to screw-capped vials containing 5 ml of RPMI1640 media to which different concentrations of 2.5, 5, 10 and 20  g asafetida were added and each concentration was done in triplicates. Each run also included control. The mortality of parasitoids was measured by the slide and the enzyme-linked immunosorbent assay (ELISA) methods. RESULTS: After 72 h, asafetida inhibited growth of parasites in all doses in stationary and logarithmic phases. The ELISA measurement suggested that the viability of parasites significantly decreased after 48h (P < 0.05). CONCLUSION: The results show that asafetida could prevent from growth and viability of parasites and this oleo gum resin can be useful for treatment of @entity3 .

title: Antileishmanial activity of Ferula assa-foetida oleo gum resin against XXXX : An in vitro study.

answer: @entity6


abstract: AIM: To investigate the safety and effectiveness of endoscopic therapy with a @entity3 -eluting balloon (PEB) for biliary @entity2 ( @entity2 ) after liver transplantation (LT). METHODS: This prospective pilot study enrolled 13 consecutive eligible @entity0 treated for symptomatic @entity2 after LT at the University Hospital of M  nster between January 2011 and March 2014. The @entity0 were treated by endoscopic therapy with a PEB and followed up every 8 wk by endoscopic retrograde cholangiopancreatography (ERCP). In cases of re-stenosis, further @entity1 with a PEB was performed. Follow-up was continued until 24 mo after the last intervention. RESULTS: Initial technical feasibility, defined as successful @entity1 with a PEB during the initial ERCP procedure, was achieved in 100% of cases. Long-term clinical success (LTCS), defined as no need for further endoscopic intervention for at least 24 mo, was achieved in 12 of the 13 @entity0 (92.3%). The mean number of endoscopic interventions required to achieve LTCS was only 1.7    1.1. Treatment failure, defined as the need for definitive alternative treatment, occurred in only one @entity0 , who developed recurrent stenosis with increasing bile duct dilatation that required stent placement. CONCLUSION: Endoscopic therapy with a PEB is very effective for the treatment of @entity2 after LT, and seems to significantly shorten the overall duration of endoscopic treatment by reducing the number of interventions needed to achieve LTCS.

title: @entity3 -eluting @entity1 of biliary XXXX after liver transplantation.

answer: @entity2


abstract: AIM: To investigate the safety and effectiveness of endoscopic therapy with a @entity3 -eluting balloon (PEB) for biliary @entity2 ( @entity2 ) after liver transplantation (LT). METHODS: This prospective pilot study enrolled 13 consecutive eligible @entity0 treated for symptomatic @entity2 after LT at the University Hospital of M  nster between January 2011 and March 2014. The @entity0 were treated by endoscopic therapy with a PEB and followed up every 8 wk by endoscopic retrograde cholangiopancreatography (ERCP). In cases of re-stenosis, further @entity1 with a PEB was performed. Follow-up was continued until 24 mo after the last intervention. RESULTS: Initial technical feasibility, defined as successful @entity1 with a PEB during the initial ERCP procedure, was achieved in 100% of cases. Long-term clinical success (LTCS), defined as no need for further endoscopic intervention for at least 24 mo, was achieved in 12 of the 13 @entity0 (92.3%). The mean number of endoscopic interventions required to achieve LTCS was only 1.7    1.1. Treatment failure, defined as the need for definitive alternative treatment, occurred in only one @entity0 , who developed recurrent stenosis with increasing bile duct dilatation that required stent placement. CONCLUSION: Endoscopic therapy with a PEB is very effective for the treatment of @entity2 after LT, and seems to significantly shorten the overall duration of endoscopic treatment by reducing the number of interventions needed to achieve LTCS.

title: XXXX -eluting @entity1 of biliary @entity2 after liver transplantation.

answer: @entity3


abstract: AIM: To investigate the safety and effectiveness of endoscopic therapy with a @entity3 -eluting balloon (PEB) for biliary @entity2 ( @entity2 ) after liver transplantation (LT). METHODS: This prospective pilot study enrolled 13 consecutive eligible @entity0 treated for symptomatic @entity2 after LT at the University Hospital of M  nster between January 2011 and March 2014. The @entity0 were treated by endoscopic therapy with a PEB and followed up every 8 wk by endoscopic retrograde cholangiopancreatography (ERCP). In cases of re-stenosis, further @entity1 with a PEB was performed. Follow-up was continued until 24 mo after the last intervention. RESULTS: Initial technical feasibility, defined as successful @entity1 with a PEB during the initial ERCP procedure, was achieved in 100% of cases. Long-term clinical success (LTCS), defined as no need for further endoscopic intervention for at least 24 mo, was achieved in 12 of the 13 @entity0 (92.3%). The mean number of endoscopic interventions required to achieve LTCS was only 1.7    1.1. Treatment failure, defined as the need for definitive alternative treatment, occurred in only one @entity0 , who developed recurrent stenosis with increasing bile duct dilatation that required stent placement. CONCLUSION: Endoscopic therapy with a PEB is very effective for the treatment of @entity2 after LT, and seems to significantly shorten the overall duration of endoscopic treatment by reducing the number of interventions needed to achieve LTCS.

title: @entity3 -eluting XXXX of biliary @entity2 after liver transplantation.

answer: @entity1


abstract: OBJECTIVE: To compare the distribution and concentrations of @entity11 in @entity0 coronal dentin. METHODS: The localization of five types of MMP was performed using immunohistochemistry. Molars were demineralized and sectioned into 5   m thick specimens. All specimens were randomly divided into five groups according to the antibodies. Each group contained two subgroups (n = 6). Immunoreactivity of each subgroup was visualized with @entity8 solution or @entity4 and observed under microscopy respectively. Molars were sectioned into slices. The slices were divided into two groups according to superficial or deep dentin and pulverized to fine powder. After dentin protein was extracted, the concentrations of @entity9 , 8, 9 were detected by using fluorescent microsphere immunoassay. RESULTS: Immunohistochemical staining revealed that @entity10 were highly concentrated in the deep dentin. However, intense immunoreactivities of @entity1 , 8, 9 were identified in a 6-10   m wide zone adjacent to the dentino-enamel junction. The content of @entity5 in superficial layer and deep layer of dentin were (0.037  0.025) and (0.433  0.089) ng/mg. The content of @entity1 in superficial layer and deep layer of dentin were (0.445  0.115) and (2.730  0.712) ng/mg. The content of @entity3 in superficial layer and deep layer of dentin were (0.071  0.069) and (0.460  0.108) ng/mg. The content of @entity6 in superficial layer and deep layer of dentin were (0.586  0.246) and (6.159  0.948) ng/mg. The content of @entity2 in superficial layer and deep layer of dentin were (0.384  0.185) and (1.460  0.251) ng/mg. The concentrations of all tested @entity7 were significantly higher in deep dentin than those in superficial dentin (P < 0.05). CONCLUSIONS: There are five types of MMP contained in @entity0 coronal dentin, and the distribution of MMP shows a decreasing trend from the deep dentin to the superficial dentin.

title: [Localization and quantitative detection of matrix metalloproteinase in XXXX coronal dentine].

answer: @entity0


abstract: @entity0 is generally accompanied by abnormal levels of growth hormone and adrenal @entity2 , hormones known to modulate postpneumonectomy (post-PNX) compensatory lung growth. Thus, we examined the possibility that @entity0 may affect post-PNX lung growth processes. Left PNX was performed in young @entity0 @entity1 ( @entity3 -induced; 75 mg/kg body weight) (DM-PNX) and in control @entity1 (C-PNX), for comparison with sham-operated control @entity1 (C-SHAM). The @entity1 were permitted free access to food and water. Examination at day 7 after surgery showed that right lung absolute dry weight and absolute DNA, collagen and @entity4 contents were increased in C-PNX and DM-PNX @entity1 (but only C-PNX values reached those of both lungs in C-SHAM @entity1 ). Body weights (BW) of DM-PNX @entity1 were lower than those of C-PNX and C-SHAM @entity1 . Lung DNA/BW in C-PNX and DM-PNX @entity1 were comparable, and matched values for both lungs in C-SHAM @entity1 . Lung dry weight/BW, collagen/BW, and @entity4 /BW in DM-PNX @entity1 exceeded values in C-PNX @entity1 and even more for values of both lungs in C-SHAM @entity1 . Data of another experiment, comparing DM-PNX @entity1 with body weight-matched (by food limitation) PNX and control @entity1 (WMC-PNX and WMC-SHAM @entity1 , respectively) indicated comparable lung absolute DNA contents in DM-PNX and WMC-PNX @entity1 (which matched values for both lungs in WMC-SHAM @entity1 ), however, lung absolute collagen and elastic contents were greater in the DM-PNX @entity1 .(ABSTRACT TRUNCATED AT 250 WORDS)

title: Effects of @entity3 -induced XXXX on postpneumonectomy lung growth and connective tissue levels.

answer: @entity0


abstract: @entity0 is generally accompanied by abnormal levels of growth hormone and adrenal @entity2 , hormones known to modulate postpneumonectomy (post-PNX) compensatory lung growth. Thus, we examined the possibility that @entity0 may affect post-PNX lung growth processes. Left PNX was performed in young @entity0 @entity1 ( @entity3 -induced; 75 mg/kg body weight) (DM-PNX) and in control @entity1 (C-PNX), for comparison with sham-operated control @entity1 (C-SHAM). The @entity1 were permitted free access to food and water. Examination at day 7 after surgery showed that right lung absolute dry weight and absolute DNA, collagen and @entity4 contents were increased in C-PNX and DM-PNX @entity1 (but only C-PNX values reached those of both lungs in C-SHAM @entity1 ). Body weights (BW) of DM-PNX @entity1 were lower than those of C-PNX and C-SHAM @entity1 . Lung DNA/BW in C-PNX and DM-PNX @entity1 were comparable, and matched values for both lungs in C-SHAM @entity1 . Lung dry weight/BW, collagen/BW, and @entity4 /BW in DM-PNX @entity1 exceeded values in C-PNX @entity1 and even more for values of both lungs in C-SHAM @entity1 . Data of another experiment, comparing DM-PNX @entity1 with body weight-matched (by food limitation) PNX and control @entity1 (WMC-PNX and WMC-SHAM @entity1 , respectively) indicated comparable lung absolute DNA contents in DM-PNX and WMC-PNX @entity1 (which matched values for both lungs in WMC-SHAM @entity1 ), however, lung absolute collagen and elastic contents were greater in the DM-PNX @entity1 .(ABSTRACT TRUNCATED AT 250 WORDS)

title: Effects of XXXX -induced @entity0 on postpneumonectomy lung growth and connective tissue levels.

answer: @entity3


abstract: OBJECTIVE: To explore the efficacy and safety of designed early conversion from @entity9 (CNI) to @entity7 (SRL) as major immunosuppressive therapy in renal transplant recipients with stable renal function. METHODS: A prospective, open-label and non-randomized control study was performed for 112 renal transplant recipients (3-6 months post-operation) with stable renal function between June 2008 and June 2011. The @entity0 in SRL group (n = 57) switched to @entity7 while those in CNI group (n = 55) continued CNI. The dosing of @entity8 mofetil and @entity2 had no change. They were followed up for at least 24 months to evaluate the acute rejection, @entity0 and graft survival, renal function, estimated glomerular filtration rate (eGFR), blood lipids, blood @entity3 , liver function and urinary protein at 1, 6, 12 and 24 months after inclusion. Adverse events were also recorded. RESULTS: The serum @entity5 of SRL group decreased significantly after conversion ( (89.2    24.7), (87.6    23.8), (86.1    20.4), (86.7    19.7) vs (117.0    16.3)   mol/L, all P < 0.05). CNI group showed no improvement of renal function.SRL group had a significantly higher eGFR than CNI group (P < 0.05). Among 3 cases of acute rejection, there were 2 in SRL group and 1 in CNI group (P > 0.05). Blood lipids in SRL group increased significantly at 1 month after conversion (P < 0.05) and reverted back to average level after intervention (P > 0.05).SRL group had a drop of hemoglobin level within the normal range. Two @entity0 in SRL group developed @entity6 and another 2 @entity0 had oral ulcer. They all improved after treatment. During follow-ups, 1 case of mild @entity4 was found in SIR group. Three @entity0 were diagnosed with @entity1 (1 in SRL group vs 2 in CNI group). CONCLUSIONS: Early conversion from CNI to SRL as major immunosuppressive therapy in renal transplant recipients with stable renal function further improves renal function. There is no higher rate of acute rejection during follow-up.Elevated blood lipids after conversion may be easily controlled. No other adverse events are found.

title: [Early conversion from XXXX to sirolimusto after renal transplantation:a prospective, open-label and non-randomized control study].

answer: @entity9


abstract: @entity4 are excellent stabilizers of triplex DNA. Recent studies in our laboratory revealed a remarkable structural specificity of @entity4 in the induction and stabilization of triplex DNA. @entity7 ( @entity5 ) showed optimum efficacy amongst a series of synthetic @entity6 in stabilizing triplex DNA. To utilize the potential of this finding in developing an anti-gene strategy for @entity0 , we treated MCF-7 cells with a 37mer oligonucleotide to form triplex DNA in the up-stream regulatory region of the @entity2 oncogene in the presence of @entity5 . As individual agents, the oligonucleotide and @entity5 did not downregulate @entity2 mRNA in the presence of @entity1 . Complexation of the oligonucleotide with 2 mM @entity5 reduced @entity2 mRNA signal by 65% at 10 microM oligonucleotide concentration. In contrast, a control oligonucleotide had no significant effect on @entity2 mRNA. The expression of @entity3 oncogene was not significantly altered by the triplex forming oligonucleotide (TFO). @entity5 was internalized within 1 h of treatment; however, it had no significant effect on the level of natural @entity4 . These data indicate that selective utilization of synthetic @entity4 and TFOs might be an important strategy to develop anti-gene-based therapeutic modalities for @entity0 .

title: Suppression of @entity2 oncogene expression by a polyamine-complexed triplex forming oligonucleotide in MCF-7 XXXX cells.

answer: @entity0


abstract: @entity4 are excellent stabilizers of triplex DNA. Recent studies in our laboratory revealed a remarkable structural specificity of @entity4 in the induction and stabilization of triplex DNA. @entity7 ( @entity5 ) showed optimum efficacy amongst a series of synthetic @entity6 in stabilizing triplex DNA. To utilize the potential of this finding in developing an anti-gene strategy for @entity0 , we treated MCF-7 cells with a 37mer oligonucleotide to form triplex DNA in the up-stream regulatory region of the @entity2 oncogene in the presence of @entity5 . As individual agents, the oligonucleotide and @entity5 did not downregulate @entity2 mRNA in the presence of @entity1 . Complexation of the oligonucleotide with 2 mM @entity5 reduced @entity2 mRNA signal by 65% at 10 microM oligonucleotide concentration. In contrast, a control oligonucleotide had no significant effect on @entity2 mRNA. The expression of @entity3 oncogene was not significantly altered by the triplex forming oligonucleotide (TFO). @entity5 was internalized within 1 h of treatment; however, it had no significant effect on the level of natural @entity4 . These data indicate that selective utilization of synthetic @entity4 and TFOs might be an important strategy to develop anti-gene-based therapeutic modalities for @entity0 .

title: Suppression of XXXX oncogene expression by a polyamine-complexed triplex forming oligonucleotide in MCF-7 @entity0 cells.

answer: @entity2


abstract: Background. @entity2 by @entity1 is one of the most common types of @entity3 in the permanent dentition among @entity0 and teenagers. Aim. The aim of this study was to report the treatment performed to an atypical @entity1 in a maxillary central incisor of a young @entity0 by means of reattachment of the tooth fragment. Case Description. A 12-year-old male @entity0 suffered a vertical crown @entity2 to the maxillary right central incisor. After clinical and radiographic examinations, a conservative restorative treatment which consisted in the reattachment of the tooth fragment with flow resin was performed in order to preserve the dental element and to obtain maximum aesthetics. Conclusion. The reattachment of fractured fragment is a fast and easy technique that can be used successfully as an option to restore dental element which suffered @entity1 . Clinical Significance. This technique restores the aesthetics and function of the dental element with minimal discomfort to the @entity0 .

title: Fragment reattachment after atypical crown XXXX in maxillary central incisor.

answer: @entity2


abstract: Introduction. @entity6 is a rare monosymptomatic hypochondriacal @entity5 according to The Diagnostic and Statistical Manual of @entity2 (5th ed.; @entity7 ; American Psychiatric Association, 2013). It can be a primary disorder or associated with an underlying @entity1 . It commonly presents as @entity8 , and less than 1% may be fungi related. We present this case as it is a rare presentation of a rare condition. Case Presentation. Our @entity0 is a 60-year-old Caucasian @entity0 who presented with a 7-year history of delusional infestation manifested as a disseminated @entity4 . He had previously been reviewed by multiple physicians for the same with no @entity3 diagnosed. After multiple reviews and thorough investigation we diagnosed him with a likely @entity6 . As is common with this @entity0 cohort he refused @entity2 review or antipsychotic medication. Conclusion. A delusion of a disseminated @entity4 is a rare condition. It is exceedingly difficult to treat as these @entity0 often refuse to believe the investigation results and diagnosis. Furthermore, they either refuse or are noncompliant with treatment. Multidisciplinary outpatient evaluation may be the best way to allay @entity0 fears and improve treatment compliance.

title: XXXX of disseminated fungosis.

answer: @entity8


abstract: With present implantable defibrillators, the ability to vary the defibrillation technique has been shown to increase the number of @entity0 suitable for transvenous system. As newer waveforms become available, the need for a flexible device may change. In addition, although it has been shown that the option of biphasic waveform may increase the defibrillation efficacy, this may depend upon the shape of the biphasic waveform used. Thirty @entity0 undergoing transvenous defibrillator implant were included in the study. In 20 @entity0 (group I), defibrillation efficacy of simultaneous monophasic, sequential monophasic, and biphasic waveform with 50% tilt was determined randomly. Similarly, in ten @entity0 (group II) testing of simultaneous monophasic shocks and biphasic waveforms with 65% and 80% tilt was performed in random order. The electrode system used consisted of two transvenous leads and a subcutaneous patch in all 30 @entity0 . In group I, 50% tilt biphasic waveform consistently provided similar or better defibrillation efficacy compared to monophasic waveforms (biphasic 7.5 +/- 5.1 joules vs simultaneous 17 +/- 7.8 joules, P < 0.01; and vs sequential 17 +/- 8.4 joules, P < 0.01). In group II, 65% tilt biphasic pulse required less energy for defibrillation as compared with simultaneous monophasic shocks (9.6 +/- 4.5 joules vs 15.6 +/- 5.1 joules, P = 0.04). No significant difference was observed in terms of defibrillation threshold between 80% tilt @entity1 and simultaneous monophasic pulses (11.8 +/- 6 joules vs 15.6 +/- 5.1 joules, P = NS). @entity1 with smaller tilt delivered using a triple lead system more uniformly improved defibrillation threshold over standard monophasic waveforms.

title: Comparison of biphasic and monophasic pulses: does the advantage of XXXX depend on the waveshape?

answer: @entity1


abstract: The past 40   years have seen significant improvements in both event-free and overall survival for @entity0 with acute lymphoblastic and @entity6 ( @entity3 and @entity6 , respectively). Serial national and international clinical trials have optimized the use of conventional chemotherapeutic drugs and, along with improvements in supportive care that have enabled the delivery of more intensive regimens, have been responsible for the major improvements in @entity0 outcome seen over the past few decades. However, the benefits of dose intensification have likely now been maximized, and over the same period, the identification of new cytotoxic drugs has been limited. Therefore, challenges remain if survival is to be improved further. In @entity3 , 5-year-survival rates of over 85% have been achieved with risk-stratified therapy, but a notable minority of @entity0 will still not be cured. In @entity6 , different challenges remain. A slower improvement in overall survival has taken place in this @entity0 population. Despite the obvious morphological heterogeneity of @entity6 blasts, biological stratification is comparatively limited, and translation into risk-stratified therapeutic approaches has only best characterized by the use of @entity5 for t(15;17)-positive @entity6 . Even where prognostic markers have been identified, limited therapeutic options or multi-drug resistance of @entity6 blasts has limited the impact on @entity0 benefit. For both, the acute morbidities of current treatment remain significant and may be life-threatening alone. In addition, the @entity1 Survivor Study (CCSS) highlighted many @entity4 survivors develop one or more chronic medical conditions attributable to treatment (1, 2). As the biology of leukemogenesis has become better understood, key molecules and intracellular pathways have been identified that offer the possibility of targeting directly the @entity4 cells while sparing normal cells. Consequently, there is now a drive to develop novel @entity4 -specific or "targeted" therapies. These new classes of drugs will have mechanisms of action, @entity2 , and therapeutic indices quite different from conventional cytotoxic drugs previously encountered, thus rendering current clinical trial methodologies inappropriate. Clinical trial methods will need to be adapted to accommodate these features of these new classes of drugs. This review will address the challenges and some of the techniques for developing clinical trials for targeted therapies.

title: Challenges of clinical trial design for targeted agents against XXXX .

answer: @entity4


abstract: This investigation aims to analyze the profile of long-term evolution of @entity6 in @entity0 and adolescents and outcomes after the control of recurrences. The cohort involved 702 @entity0 followed from 1.3 to 16.9   years covering the two periods, before and after the implementation of a prevention program. Besides the establishment of the Reference Center in the State of Minas Gerais and the implementation of strategies to promote the compliance to prophylaxis, a project for education of health professionals was carried out in 23 cities. In addition to the clinical and epidemiological profile, the severity of the disease was analyzed. Mixed lesions were found in 27.1%, @entity3 in 72.9%, and complete regression of the @entity1 was seen in 34.4% of the @entity0 , mostly presenting @entity4 . The recurrence rate per @entity0 -year was 0.058 and out of a total of 85 recurrences, 21.4% occurred in the first and 7.5% in the second period. More severe degrees of @entity5 and significant valvar sequels presented a higher prevalence in @entity0 with recurrences. The comparative analysis between the two periods showed no changes regarding the age at the primary attack, gender, type, and site of @entity1 and affected joints; however, important modifications in the indices of severity were observed after the control of recurrences. A significant decrease in the prevalence of severe @entity5 , obstructive valvar sequels, hospital admissions, surgical approach, and @entity2 was seen. This investigation showed that although the clinical profile of presentation remains unchanged, the control of repeated attacks can improve the morbimortality rates. In this context, the secondary prophylaxis should be the first priority in the control of the disease in developing countries, taking into account the difficulties found for effective primordial and primary prevention.

title: XXXX prevention program: long-term evolution and outcomes.

answer: @entity6


abstract: Because of a family history of @entity0 , a 51-year-old @entity1 underwent bilateral subcutaneous mammectomy in 1988. In February 1994 she presented with a nodule in the supramedial quadrant on the left. Needle biopsy suggested @entity3 which was confirmed histologically. A 1.5 cm @entity2 was removed together with a 3 cm reliquat of glandular tissue. Twelve axillary nodes were dissected and were found to be free of @entity2 . Hormone receptors were positive. Post-operative radiotherapy was performed. The outcome is unchanged at 6 months. Bilateral subcutaneous mammectomy can be proposed as a preventive measure in @entity1 at risk, but as demonstrated by this case, exeresis is usually incomplete. The level of protection actually achieved is thus questionable. Clinicians should be aware of the risk of @entity0 developing after such elective operations since early screening programmes and the development of genetic methods based on the search for @entity5 and @entity4 genes will undoubtedly increase the number of @entity1 requesting preventive measures.

title: [ XXXX after preventive subcutaneous mastectomy].

answer: @entity0


abstract: @entity3 hominis cysts were concentrated from @entity0 faeces by repeated washing in distilled water and centrifugation on Ficoll-Paque. This procedure gave a concentrated suspension of cysts without yielding any non-cystic forms. The cysts were examined by both transmission (TEM) and @entity2 ( @entity2 ). Cysts were surrounded by a fibrillar layer that appeared porous in @entity2 . Many @entity1 without the fibrillar layer were also visible in @entity2 . They were variable in shape but mostly circular to oval. The diameter of the cyst without the fibrillar layer was 3.5 microns in both TEM and @entity2 . The nuclear structure was typical of @entity3 and exhibited multiple mitochondria with poorly developed cristae. Glycogen was present in small to large clumps in the cytoplasm. The cyst wall was 5-100 nm thick and was bounded internally by an electron-dense plasmalemma.

title: Ultrastructure of XXXX hominis cysts.

answer: @entity3


abstract: AIM: A ligation-assisted endoscopic enucleation (EE-L) technique was developed and was evaluated to determine its efficacy and safety for treating muscularis propria-originating @entity2 (<10 mm). METHOD: EE-L was used to treat 13 such @entity0 between January 2011 and January 2014. The @entity1 was sucked into a transparent cap and ligated at its base by a @entity4 attached to the tip of the endoscope. With the creation of a pseudo-stalk, the @entity1 was then enucleated using endoscopic dissection and the .wound was closed with clips. RESULTS: All @entity1 (median diameter,6.8 (4-10) mm were successfully (procedure time 19 (11-27) minutes) and histopathological examination identified 11 (84.6%) to be @entity5 and 2 (15.4%) low risk @entity1 ( @entity1 ). No perforations or massive @entity3 occurred and there were no recurrences during a follow-up of 3-39 months. CONCLUSIONS: EE-L is a successful technique for the removal of small muscularis propria @entity2 with few complications and enables the histopathological diagnosis. In this study, all the resected lesions had a benign pathology. This article is protected by copyright. All rights reserved.

title: Ligation-assisted endoscopic enucleation for the treatment of XXXX originating in the muscularis propria.

answer: @entity2


abstract: Plant lipoxygenases are thought to be involved in the biosynthesis of lipid-derived signaling molecules. The potential involvement of a specific @entity0 @entity4 isozyme, @entity3 , in the biosynthesis of the plant growth regulators @entity2 (JA) and @entity1 was investigated. Our characterization of @entity3 indicates that the protein is targeted to chloroplasts. The physiological role of this chloroplast @entity4 was analyzed in transgenic plants where cosuppression reduced @entity3 accumulation. The reduction in @entity3 levels caused no obvious changes in plant growth or in the accumulation of @entity1 . However, the wound-induced accumulation of JA observed in control plants was absent in leaves of transgenic plants that lacked @entity3 . Thus, @entity3 is required for the wound-induced synthesis of the plant growth regulator JA in leaves. We also examined the expression of a wound- and JA-inducible @entity0 gene, vsp, in transgenic and control plants. Leaves of transgenic plants lacking @entity3 accumulated less vsp mRNA than did control leaves in response to wounding. This result suggests that wound-induced JA (or some other @entity3 -requiring component of the wound response pathway) is involved in the wound-induced regulation of this gene.

title: A chloroplast @entity4 is required for wound-induced XXXX accumulation in @entity0 .

answer: @entity2


abstract: Plant lipoxygenases are thought to be involved in the biosynthesis of lipid-derived signaling molecules. The potential involvement of a specific @entity0 @entity4 isozyme, @entity3 , in the biosynthesis of the plant growth regulators @entity2 (JA) and @entity1 was investigated. Our characterization of @entity3 indicates that the protein is targeted to chloroplasts. The physiological role of this chloroplast @entity4 was analyzed in transgenic plants where cosuppression reduced @entity3 accumulation. The reduction in @entity3 levels caused no obvious changes in plant growth or in the accumulation of @entity1 . However, the wound-induced accumulation of JA observed in control plants was absent in leaves of transgenic plants that lacked @entity3 . Thus, @entity3 is required for the wound-induced synthesis of the plant growth regulator JA in leaves. We also examined the expression of a wound- and JA-inducible @entity0 gene, vsp, in transgenic and control plants. Leaves of transgenic plants lacking @entity3 accumulated less vsp mRNA than did control leaves in response to wounding. This result suggests that wound-induced JA (or some other @entity3 -requiring component of the wound response pathway) is involved in the wound-induced regulation of this gene.

title: A chloroplast XXXX is required for wound-induced @entity2 accumulation in @entity0 .

answer: @entity4


abstract: Plant lipoxygenases are thought to be involved in the biosynthesis of lipid-derived signaling molecules. The potential involvement of a specific @entity0 @entity4 isozyme, @entity3 , in the biosynthesis of the plant growth regulators @entity2 (JA) and @entity1 was investigated. Our characterization of @entity3 indicates that the protein is targeted to chloroplasts. The physiological role of this chloroplast @entity4 was analyzed in transgenic plants where cosuppression reduced @entity3 accumulation. The reduction in @entity3 levels caused no obvious changes in plant growth or in the accumulation of @entity1 . However, the wound-induced accumulation of JA observed in control plants was absent in leaves of transgenic plants that lacked @entity3 . Thus, @entity3 is required for the wound-induced synthesis of the plant growth regulator JA in leaves. We also examined the expression of a wound- and JA-inducible @entity0 gene, vsp, in transgenic and control plants. Leaves of transgenic plants lacking @entity3 accumulated less vsp mRNA than did control leaves in response to wounding. This result suggests that wound-induced JA (or some other @entity3 -requiring component of the wound response pathway) is involved in the wound-induced regulation of this gene.

title: A chloroplast @entity4 is required for wound-induced @entity2 accumulation in XXXX .

answer: @entity0


abstract: INTRODUCTION: Although extensive research has been conducted on @entity1 markers, a singular clinically applicable marker has not been found yet. The objective of this study was to evaluate the sensitivity and the specificity of @entity2 ( @entity2 ) mRNA and @entity3 ( @entity3 ) mRNA biomarkers in peripheral blood to detect @entity1 individually and simultaneously. METHODS: Thirty @entity0 affected by @entity1 and 30 healthy individuals were studied in this research. Three vials of cDNA were made from each sample after taking peripheral blood samples and extracting total RNA. Each sample was examined by the real-time RT-PCR technique. The result from each vial was then compared with the sensitivity of overall marker. RESULTS: The @entity2 mRNA was positive in 24 out of 30 @entity1 @entity0 . Hence, its sensitivity was determined at 80%, differing significantly from that observed in healthy individuals, where 11 positive cases were seen. The overall sensitivity of this marker was significantly associated with positivity in vials 2 and 3 but not in vial 1. The @entity3 mRNA was positive in 21 out of 30 @entity0 , indicating 70% sensitivity. This finding significantly differed from that in healthy individuals. The overall sensitivity of this marker was significantly associated with positivity in vials 1 and 3, but not in vial 2. In 93.3% of the @entity0 , at least one positive marker was observed. CONCLUSION: The mentioned mRNA could be suggested as sensitive and specific markers in peripheral blood for primary diagnosis of @entity1 .

title: Expression of two basic mRNA biomarkers in peripheral blood of XXXX with non-small cell lung cancer detected by real-time rt-PCR, individually and simultaneously.

answer: @entity0


abstract: BACKGROUND: Approximately 75  % of @entity0 with @entity6 present with stage I disease, and the probability of long-term survival approaches 100  %. However, the standard adjuvant treatment for @entity1 @entity0 remains controversial, and there is no uniform consensus in the literature. The present study was performed to evaluate treatment preference and outcomes for @entity0 with @entity3 . MATERIALS AND METHODS: From 1997 to 2013, 282 @entity0 with histologically confirmed stage IA and IB @entity6 who underwent orchiectomy were included. The outcomes of three management options and survivals were retrospectively analyzed. The prognostic significance of risk factors for relapse on survival was evaluated by univariate and multivariate analysis; in addition, the factors predicting relapse were also evaluated by logistic regression analysis. RESULTS: Of the 282 @entity0 with @entity1 , 130 (46.1) received adjuvant radiotherapy (RT), 80 (28.4  %) were treated with adjuvant @entity5 , while the remaining 72 @entity0 (25.5  %) underwent surveillance. At the time of analysis, the median follow-up period of 38.5  months; relapses were observed in 16 @entity0 (22.3  %) on surveillance, in one @entity0 (1.2  %) treated with adjuvant @entity5 and in ten @entity0 (%7.7) who received adjuvant RT. The 5-year @entity2 ( @entity2 ) rate for @entity0 who underwent surveillance was worse than those of @entity0 treated with adjuvant @entity5 and RT (64.2 vs. 97.7 vs. 91.9  %, respectively; p  <  0.001). However, the 5-year @entity4 ( @entity4 ) rate for @entity0 on surveillance was similar compared with the adjuvant treatment groups (100 vs. 92.3 vs. 97.4  %, respectively; p  =  0.44). Univariate analysis showed that only the treatment approach (surveillance vs. adjuvant @entity5 vs. adjuvant RT) for @entity2 (p  <  0.001), invasion of the rete testis (p  =  0.041) and the presence of relapse (p  <  0.001) for @entity4 were important prognostic indicators. Multivariate analysis indicated that the treatment strategy for @entity2 (p  <  0.001, HR 0.34) was an independent prognostic factor. Furthermore, a logistic regression analysis showed that adjuvant treatment was found to be an independent factor for predicting relapse (p  =  0.004, odds ratio: 0.39). CONCLUSIONS: Our results indicate that adjuvant treatment with @entity5 or RT is associated with improved @entity2 compared with surveillance for @entity0 with @entity3 after orchiectomy. Moreover, the treatment strategy is an important prognostic indicator for @entity2 and a predictive factor for relapse. Although adjuvant treatment, especially @entity5 , seems to be a suitable treatment for @entity0 with risk factors for relapse, surveillance is still feasible and the preferred management option after radical orchiectomy in @entity0 with @entity1 . More reliable predictive factors are needed to make treatment decisions.

title: Treatment preferences in stage IA and IB XXXX : multicenter study of Anatolian Society of Medical Oncology.

answer: @entity6


abstract: OBJECTIVE: There is a need to determine which response measures in @entity3 trials are most predictive of good long-term renal function. We used data from the @entity4 - @entity3 Trial to evaluate the performance of @entity1 , serum @entity2 ( @entity5 ), and urinary red blood cells (RBCs) as predictors of good long-term renal outcome. METHODS: @entity0 from the @entity4 - @entity3 Trial with @entity1 , serum @entity5 , and urinary RBC measurements at 3, 6, or 12 months and with a minimum of 7 years of followup were included (n   =   76). We assessed the ability of these clinical biomarkers at 3, 6, and 12 months after randomization to predict good long-term renal outcome (defined as a serum @entity5 value  <=1.0 mg/dl) at 7 years. Receiver operating characteristic curves were generated to assess parameter performance at these time points and to select the best cutoff for individual parameters. Sensitivity and specificity were calculated for the parameters alone and in combination. RESULTS: A @entity1 value of <0.8 gm/day at 12 months after randomization was the single best predictor of good long-term renal function (sensitivity 81% and specificity 78%). The addition of serum @entity5 to @entity1 as a composite predictor did not improve the performance of the outcome measure; addition of urinary RBCs as a predictor significantly decreased the sensitivity to 47%. CONCLUSION: This study demonstrates that the level of @entity1 at 12 months is the individual best predictor of long-term renal outcome in @entity0 with @entity3 . Inclusion of urinary RBCs as part of a composite outcome measure actually undermined the predictive value of the trial data. We therefore suggest that urinary RBCs should not be included as a component of clinical trial response criteria in @entity3 .

title: Predictors of long-term renal outcome in @entity3 trials: lessons learned from the XXXX - @entity3 cohort.

answer: @entity4


abstract: OBJECTIVE: There is a need to determine which response measures in @entity3 trials are most predictive of good long-term renal function. We used data from the @entity4 - @entity3 Trial to evaluate the performance of @entity1 , serum @entity2 ( @entity5 ), and urinary red blood cells (RBCs) as predictors of good long-term renal outcome. METHODS: @entity0 from the @entity4 - @entity3 Trial with @entity1 , serum @entity5 , and urinary RBC measurements at 3, 6, or 12 months and with a minimum of 7 years of followup were included (n   =   76). We assessed the ability of these clinical biomarkers at 3, 6, and 12 months after randomization to predict good long-term renal outcome (defined as a serum @entity5 value  <=1.0 mg/dl) at 7 years. Receiver operating characteristic curves were generated to assess parameter performance at these time points and to select the best cutoff for individual parameters. Sensitivity and specificity were calculated for the parameters alone and in combination. RESULTS: A @entity1 value of <0.8 gm/day at 12 months after randomization was the single best predictor of good long-term renal function (sensitivity 81% and specificity 78%). The addition of serum @entity5 to @entity1 as a composite predictor did not improve the performance of the outcome measure; addition of urinary RBCs as a predictor significantly decreased the sensitivity to 47%. CONCLUSION: This study demonstrates that the level of @entity1 at 12 months is the individual best predictor of long-term renal outcome in @entity0 with @entity3 . Inclusion of urinary RBCs as part of a composite outcome measure actually undermined the predictive value of the trial data. We therefore suggest that urinary RBCs should not be included as a component of clinical trial response criteria in @entity3 .

title: Predictors of long-term renal outcome in XXXX trials: lessons learned from the @entity4 - @entity3 cohort.

answer: @entity3


abstract: OBJECTIVE: There is a need to determine which response measures in @entity3 trials are most predictive of good long-term renal function. We used data from the @entity4 - @entity3 Trial to evaluate the performance of @entity1 , serum @entity2 ( @entity5 ), and urinary red blood cells (RBCs) as predictors of good long-term renal outcome. METHODS: @entity0 from the @entity4 - @entity3 Trial with @entity1 , serum @entity5 , and urinary RBC measurements at 3, 6, or 12 months and with a minimum of 7 years of followup were included (n   =   76). We assessed the ability of these clinical biomarkers at 3, 6, and 12 months after randomization to predict good long-term renal outcome (defined as a serum @entity5 value  <=1.0 mg/dl) at 7 years. Receiver operating characteristic curves were generated to assess parameter performance at these time points and to select the best cutoff for individual parameters. Sensitivity and specificity were calculated for the parameters alone and in combination. RESULTS: A @entity1 value of <0.8 gm/day at 12 months after randomization was the single best predictor of good long-term renal function (sensitivity 81% and specificity 78%). The addition of serum @entity5 to @entity1 as a composite predictor did not improve the performance of the outcome measure; addition of urinary RBCs as a predictor significantly decreased the sensitivity to 47%. CONCLUSION: This study demonstrates that the level of @entity1 at 12 months is the individual best predictor of long-term renal outcome in @entity0 with @entity3 . Inclusion of urinary RBCs as part of a composite outcome measure actually undermined the predictive value of the trial data. We therefore suggest that urinary RBCs should not be included as a component of clinical trial response criteria in @entity3 .

title: Predictors of long-term renal outcome in @entity3 trials: lessons learned from the @entity4 - XXXX cohort.

answer: @entity3


abstract: OBJECTIVE: To describe and analyse the problems in self-maintaining activities among @entity3 ( @entity3 ) @entity0 aged 64 years and over. DESIGN: A case-control study. SETTING: Health Centre in Lieto, Finland, 1990-91. SUBJECTS: 61 @entity0 and 21 @entity0 with @entity3 and 183 male and 63 female sex- and age-matched controls. The @entity3 group included 8 @entity0 and 11 @entity0 who also had @entity1 . MAIN OUTCOME MEASURES: Numbers of subjects with difficulties or @entity2 in self-maintaining activities. RESULTS: The number of subjects with difficulty or @entity2 in the activities of daily living (ADL) was similar among the @entity0 and the controls, but some differences between the two groups were seen on items of mobility and instrumental activities of daily living (IADL). The @entity3 @entity0 had more difficulties or showed @entity2 in moving outdoors or walking at least 400 m. In addition, the male @entity3 @entity0 reported more difficulty or @entity2 in doing heavy housework and the female @entity0 in even doing light housework than the controls. CONCLUSION: The study indicated that the female @entity3 @entity0 in particular have a great need for assistance in self-maintaining functions. This information is valuable for local primary health care planning.

title: XXXX and self-maintaining functions in the elderly--a population-based study.

answer: @entity3


abstract: Adult @entity3 (AGCT) is an uncommon @entity1 of the ovary with potential for @entity2 and late recurrence. The most important prognostic factor for AGCT is @entity1 stage. Thus, cytological assessment of pleural or @entity4 fluids is crucial for initial @entity1 and subsequent @entity0 management. We report herein two cases of ovarian AGCT presenting with exfoliated @entity1 cells in pleural and @entity4 fluid. The first case involved a 61-year-old @entity0 who presented with stage Ic (a) AGCT. Seven years after initial diagnosis, @entity5 and @entity5 were identified. The second case involved a 50-year-old @entity0 who presented with stage IV AGCT with massive @entity4 and right @entity5 . Fluid cytology from both cases showed cohesive or loose clusters of small uniform neoplastic cells with round-to-oval nuclei, coffee-bean-shaped nuclear grooves, small nucleoli, and scant cytoplasm. Call-Exner bodies were also observed in these cytologic specimens. In the differential diagnosis of small monomorphic @entity1 cells in @entity5 or @entity4 , coffee-bean-shaped nuclear grooves and cell clusters forming Call-Exner bodies are diagnostic clues of AGCT.

title: Cytologic features of ovarian granulosa cell tumors in XXXX .

answer: @entity4


abstract: From 1981 to 1984, a randomized study was done by the EORTC Radiotherapy Group comparing a fractionation schedule with three fractions per day (multiple fractions per day, MFD), with or without @entity2 , to conventional fractionation. The aim of the study was to obtain improved local and regional control and survival by shortening of the treatment time in the first 2 weeks of irradiation. Three fractions of 1.6 Gy/day (4-h interval) were given during 10 irradiation days to a total of 48 Gy. After 3-4-weeks interval, a boost was given to 67.2 or 72 Gy also in three fractions per day. This schedule was compared to an identical arm with @entity2 1 g/m2/day and a third arm with conventional fractionation (70 Gy in 35 fractions, 7 weeks or 75 Gy in 44 fractions, 9 weeks). A total number of 523 @entity0 was included in the study. Acute @entity1 was much heavier in @entity0 treated with three fractions per day (Van den Bogaert et al. Int. J. Radiat. Oncol. Biol. Phys. 8: 1649-1655, 1982). Early results, communicated in 1986 (Van den Bogaert et al. Int. J. Radiat. Oncol. Biol. Phys. 12: 587-591, 1986) showed no differences in treatment outcome between the three treatment arms. Long-term results and data on late effects are now available. Survival at 5 years was 18% (SE 1.9%) and locoregional control was 27% (SE 2.9%). No statistically significant differences could be observed between the three treatment arms.(ABSTRACT TRUNCATED AT 250 WORDS)

title: The EORTC randomized trial on three fractions per day and XXXX (trial no. 22811) in advanced head and neck cancer: long-term results and side effects.

answer: @entity2


abstract: PURPOSE OF THE STUDY: Fibro- @entity5 ossificans progressive is a rare @entity1 , presumably transmitted as an autosomal dominant defect. The high level of spontaneous mutations explains the sporadic cases. Pre symptomatic diagnosis could be actually evoked by the association of progressive ossification of soft tissues with @entity3 of bones (metacarpal and metatarsal). The purpose of this study is to report a clinical case with a very severe course. CASE REPORT: A 10-year-old @entity0 developed progressive ossification of muscles and soft tissues in multiple sites neck, back, shoulders, elbows, hips and knees. The clinical course was severe due to the @entity10 and the decrease of pulmonary reserve with fixation of the chest wall. A @entity7 facilitated the diagnosis. DISCUSSION: This pattern of @entity8 together with the @entity7 defines the developmental phenotype for @entity9 ossificans. A slow course with successive thrusts occurs. Ossification progressively involves tendons, ligaments and the connective tissue of skeletal muscles. Excision of heterotopic bone is futile as the trauma of the operation can lead to the stimulation of new @entity8 at the operative site. Surgery is only useful for biopsy and histological study reveals @entity2 . The mature heterotopic bone is histologically indistinguishable from mature skeletal bone. The non skeletic muscles are characteristically spared from ossification. @entity4 often results from @entity6 due to fixation of the thoracic cage. The pathogenesis and the treatment of the disorder are unknown.

title: [ XXXX ossificans progressiva. Apropos of a case].

answer: @entity9


abstract: BACKGROUND: A palette of copy number changes in a case of adult pilocytic @entity3 analyzed by Array Comparative Genomic Hybridization (aCGH) is presented. @entity3 are specific @entity2 that are benign and biologically distinct and the molecular mechanisms responsible for their development remain unexplained. The aCGH was performed using SurePrint G3 @entity0 CGH microarrays 4   *   180  K (Agilent Technologies). To ascertain whether some of the aberrations were of constitutive nature, we also analyzed the blood sample from the same @entity0 . RESULTS: The result of aCGH analysis demonstrated differences in the @entity1 tissue when compared to normal control on the array and also to autologous DNA from @entity0 's blood. The total number of aberrations found in our case was 41 including 37 deletions and 4 amplifications. Whole chromosomal gains and losses were not observed. Collectively, our results showed three deletions and one amplification at 1p, two deletions at 2q, two deletions at 4q, two deletion at 5q, two deletions at 7p and two deletions at 7q; there were also three deletions at 8q, one deletion at 9p, one deletion at 10p, three deletions and one amplification at 10q. Chromosome 11 showed two deletions at 11p, while there was one deletion at 12p and one at 12q. Four deletions at 14q; two deletions at 15q, one amplification at 17q and one deletion at 17q; one deletion at 18p, two deletions at 22q and finally one deletion at Xp and one deletion and one amplification at Xq. Among the signaling pathways, olfactory transduction, Fc gamma R-mediated phagocytosis and @entity4 signaling pathway showed significant enrichment ascertained by gene ontology (GO) analysis using the DAVID software. CONCLUSIONS: Our aCGH analysis is bringing subtle genomic alterations thus broadening genetic spectrum of adult pilocytic @entity3 in order to offer new molecular biomarkers that will help in diagnostics and therapeutic decision-making.

title: Genetic changes observed in a case of adult pilocytic XXXX revealed by array CGH analysis.

answer: @entity3


abstract: INTRODUCTION: Gout is an increasingly common medical problem. The traditional risk factors of male sex and high red meat or @entity5 consumption have been joined with newer risks such as increased life expectancy, and the @entity6 ( @entity4 , @entity1 , dyslipidaemia, @entity3 ). METHODS: This was a retrospective study to determine the epidemiology, clinical features, associated conditions as well as renal related conditions in existing @entity7 @entity0 followed-up in Rheumatology outpatient clinic, Hospital Tuanku Ja'afar, Seremban. RESULTS: Over a three month period, we identified 54 gouty @entity0 on our follow-up, the majority being male, Malay ethnicity, with the age of onset in the third and fourth decades of life. Commonly associated risk factors were @entity4 , hyperlipidaemia and @entity3 . However, underlying history of @entity1 , @entity5 consumption, and family history were not commonly associated with @entity7 in our group of @entity0 . Half of our @entity0 had at least two or more joints involvement. About half of the @entity0 with @entity7 had @entity2 . CONCLUSION: Our series of @entity7 @entity0 highlight the high prevalence of cardiovascular risk factors. The high prevalence of tophi and @entity2 is a cause for concern.

title: Clinical characteristics of XXXX : a hospital case series.

answer: @entity7


abstract: This is the history of discoveries of several enzyme @entity2 markers in the awardees laboratory. The first, beta-glucuronidase, was originally related to the physiological actions of @entity3 and @entity6 . Perfection of histochemical techniques based on new substrates demonstrated the dual localization of beta-glucuronidase in endoplasmic reticulum and lysosomes. Tumor tissues, in general, are enriched with beta-glucuronidase. Next, acid phosphatase of the prostate gland possesses the distinctive property of undergoing inhibition by @entity8 . This organ-specific inhibitor was incorporated into the Fishman-Lerner method for measuring serum acid phosphatase of prostatic origin. This significantly increased the specificity of the measurement of serum acid phosphatase for @entity4 . Finally, the discovery of the Regan Isoenzyme, @entity5 ( @entity5 ) in a @entity0 with disseminated @entity1 provided a @entity2 marker useful in the management of @entity2 , in particular. Closely related to @entity5 is germ cell alkaline phosphatase which is eutopically expressed in @entity7 . Finally, radioimmunolocalization and radioimmunotherapy of @entity5 in these @entity2 have been achieved by others.

title: The 1993 ISOBM Abbott Award Lecture. Isozymes, XXXX markers and oncodevelopmental biology.

answer: @entity2


abstract: INTRODUCTION: Failure of teeth to erupt from gingival tissues at usual developmental time is called delayed @entity1 (DTE). @entity1 lead to prolonged fixed orthodontic treatment and its eventual complications. The purpose of the present study was to evaluate the effect of laser-assisted (808 nm) surgical uncovering, on the tooth emergence and orthodontic treatment of DTE. METHODS: A total of 16 orthodontic @entity0 were included in this study and were equally assigned to an experimental and a control group. Subjects for experiment consisted of eight @entity0 (6 @entity0 and 2 @entity0 ) with a mean age of 14  0.9 years. All @entity0 exhibited delayed second @entity1 . The laser wavelength was 810 nm and it was set in a continuous wave mode at a power output of 1.6 watt with a 0.3-mm diameter fiber tip. When the target tissue was sufficiently anesthetized, the tip was directed at an angle of 10 to 20 degrees to the tissue (light contact mode); and was applied continuously for approximately 12 Seconds until an acceptable tooth exposure area was visible. The @entity3 of the clinical crown ( @entity5 ) line represents the most prominent portion of the @entity4 . All orthodontic brackets are aligned along this reference and are located on @entity3 ( @entity3 ) point. The standard for adequate @entity1 was the accessibility of @entity3 of the clinical crown ( @entity5 ) for bonding the brackets. Data gathered from the @entity0 were statistically surveyed and compared by means of Tukey's Test and Analysis of Variance (ANOVA). RESULTS: All @entity0 showed good gingival status, no significant @entity2 during or immediately after the surgery, and acceptable level of healing after laser surgery. The biologic width of the teeth was preserved and no violation of this important periodontal parameter was observed. The average time for accessing the @entity3 point in experimental group was 11  1.1 weeks and the mentioned period was increased to 25  1.8 weeks in control group. The data analysis showed that in @entity0 with DTE, laser intervention significantly accelerated @entity1 (P < 0.05). CONCLUSION: Laser-assisted surgical removal of the fibrous tissue over erupting premolars (DTE) with appropriate irradiation parameters appears to be a promising adjunct to orthodontic treatment for bringing the premolar to the aligned and leveled dental arch.

title: The 808 nm Laser-Assisted Surgery as an Adjunct to Orthodontic Treatment of Delayed XXXX .

answer: @entity1


abstract: @entity1 metabolism is one of the oldest known environmental processes. The operon involved in this process is called the dsr operon. The vital role of the operon is to maintain the environmental @entity1 balance. The dsr operon of proteobacteria consists of 15 genes, viz. dsrABEFHCMKLJOPNRS. The proteins encoded by the dsr operon are essential for the transfer of @entity1 globules from periplasm to cytosol and oxidation of the stored @entity1 . In the present study we tried to analyze the probable molecular details of the DsrM proteins from a diverse set of microbial species using their sequence information. There are certain mutations in the sequences of the DsrM proteins from the different proteobacterial species. The effects of mutations in the sequences of DsrM proteins were predicted from the evolutionary point of view. This is so far the first report of its kind. Our study would therefore enable the researches to predict the hitherto unknown biochemistry of @entity1 oxidation using the @entity0 sequences of the DsrM proteins.

title: Mutation study of DsrM from Allochromatium vinosum using the XXXX sequences.

answer: @entity0


abstract: BACKGROUND: Four constructs are encompassed by the term "falls-related psychological concerns" (FrPC); "fear of falling" ( @entity3 ), "falls-related self-efficacy" ( @entity3 ), "balance confidence" (BC) and "outcome expectancy" (OE). FrPC are associated with negative consequences including physical, psychological, and social. Identifying factors associated with FrPC could inform interventions to reduce these concerns. METHODS: Sixty-two empirical papers relating to psychological factors associated with FrPC in community-dwelling older @entity0 (CDOP) were reviewed. Four levels of evidence were used when evaluating the literature: good, moderate, tentative, and none. RESULTS: Evidence that @entity1 predicted @entity3 , BC, and OE was tentative. Moderate evidence was found for @entity1 predicting @entity3 . Good evidence was found for @entity2 predicting @entity3 . Moderate evidence was found for @entity2 predicting both @entity3 and BC. No evidence was found for @entity2 predicting OE. Tentative evidence was found for @entity3 predicting @entity2 . Good and moderate evidence was found for quality of life (QoL) being predicted by @entity3 and BC respectively. Tentative evidence was found for @entity3 predicting QoL. Moderate evidence was found for QoL predicting both @entity3 and BC. No evidence was found for QoL predicting @entity3 . Good and moderate evidence was found for activity avoidance/restriction (AA/AR) being predicted by @entity3 and @entity3 respectively. Tentative evidence was found for BC and OE predicting AA/AR, as well as for AA/AR predicting @entity3 . Moderate evidence for @entity4 ( @entity4 ) predicting @entity3 was identified, however the evidence of this predicting @entity3 and BC was tentative. Evidence for @entity3 , @entity3 , and BC predicting @entity4 was tentative as was evidence to suggest @entity3 predicted coping. CONCLUSIONS: Mixed evidence has been found for the association of psychological factors in association with FrPCs. Future research should employ theoretically grounded concepts, use multivariate analysis and longitudinal designs.

title: A theoretical and empirical review of psychological factors associated with falls-related psychological concerns in community-dwelling older XXXX .

answer: @entity0


abstract: Scaffold-based @entity1 engineering is rapidly evolving the study of @entity1 progression. However, the effects of scaffolds and environment on @entity1 formation have seldom been investigated. In this study, four types of injectable hydrogels, namely, collagen type I, Matrigel, alginate and agarose gels, were loaded with @entity0 @entity5 SKOV3 cells and then injected into @entity3 subcutaneously. The growth of the @entity1 in vitro was also investigated. After four weeks, the specimens were harvested and analyzed. We found that @entity1 formation by SKOV3 cells was best supported by collagen, followed by Matrigel, alginate, control (without scaffold) and agarose in  vivo. The collagen I group exhibited a larger @entity1 volume with increased neovascularization and increased @entity4 compared with the other materials. Further, increased MMP activity, upregulated expression of laminin and fibronectin and higher levels of @entity6 and @entity2 in the collagen group revealed that the engineered @entity1 is closer to @entity0 @entity5 . In order, collagen, Matrigel, alginate, control (without scaffold) and agarose exhibited decreases in @entity1 formation. All evidence indicated that the in vivo engineered @entity1 is scaffold-dependent. Bioactive hydrogels are superior to inert hydrogels at promoting @entity1 regeneration. In particular, biomimetic hydrogels are advantageous because they provide a microenvironment that mimics the ECM of natural @entity1 . On the other hand, typical features of @entity1 cells and the expression of genes related to @entity1 were far less similar to the @entity1 in vitro, which indicated the importance of culture environment in vivo. Superior to the in vitro culture, @entity3 can be considered satisfactory in vivo 'bioreactors' for the screening of favorable cell vehicles for @entity1 engineering in vitro.

title: In vivo bioengineered XXXX based on collagen, matrigel, alginate and agarose hydrogels: a comparative study.

answer: @entity5


abstract: Haemoptysis rarely occurs in @entity6 . Most cases usually occur in @entity0 with @entity9 and major @entity3 . We observed 6 cases including 5 with @entity3 and 1 with inaugural unilateral lymph node involvement. Haemoptysis is a sign of gravity since it is the second most frequent cause of @entity4 described in the literature. In our series 4 of the 6 cases were fatal. Aspergillus colonization of a cavity is the most frequently found aggravating factor. Ideally, surgery is indicated but usually cannot be performed due to the @entity0 respiratory function and the extent of the lesions. Oral drugs have little effect. Certain authors have had success with local, initially intrabronchic anti-aspergillus treatment. CT-guided application is often helpful. Embolization may stop the @entity7 but in the long-term, a more or less voluminous haemoptysis often recurs. Other causes of @entity7 are rare. Systemic hypervascularization of @entity2 has been proposed as one mechanism other than infection. The cause may also be a simple @entity8 . Symptomatic initial treatment by embolization is also proposed in these cases. Finally, massive haemoptysis can occur by @entity5 due to a @entity1 . In our series, surgery was impossible in three @entity0 who died. In the three others, embolization was possible in 2 and the third underwent successful surgery.

title: [Hemoptysis in XXXX . Apropos of 6 cases including 4 with fatal outcome].

answer: @entity6


abstract: A national registry for @entity2 was established in France in 1993. A questionnaire is sent once a year to different health care units. The first questionnaire was analyzed in 1992: 1,893 @entity0 (53% males) were identified. 28% were over 15 years of age, 13% more than 20, and 1% over 35. Usually, diagnosis had been suggested by respiratory signs, followed by digestive tract signs and @entity1 and meconial ileus. 13% were diagnosed in screening programmes. Diagnosis was made before 1 year in 66% of the subjects (mean = 7 months). All the data collected and the functional and bacteriologic data were compared with those observed in the United States and Canada. It should also be noted that 38 @entity0 were grafted during this study year and that it is too early to analyze the general outcome for all subjects. The creation of this registry is an important step towards a better understanding of the epidemiology of @entity2 in the French population.

title: [ XXXX : comparative analysis of epidemiological data of French and North American registries].

answer: @entity2


abstract: BACKGROUND: Diagnosis of @entity6 ( @entity6 ) is important, due to the associated very high mortality. Failure to diagnose @entity6 is a problem both for the @entity0 and the clinicians. @entity1 modified albumin (IMA) has already been licensed by the US Food and Drug Administration for the diagnosis of suspected @entity5 . METHODS: @entity0 attending the @entity2 ( @entity2 ) within 6  h after having features of @entity6 were selected. IMA was done on admission. Blinded to the IMA results @entity0 were fully evaluated and a diagnosis of non-ischemic @entity4 (NICP), @entity7 ( @entity7 ) or @entity3 ( @entity3 ) was made. Later IMA results were correlated in each group. RESULTS: Mean IMA value was 56.38      23.89  u/ml in NICP group whereas in @entity7 group it was 89.00      7.76  u/ml and @entity3 group was 87.50      9.62  u/ml. This showed a sensitivity of 92% and specificity of 87%. The positive predictive value of the test was 88% and negative predictive value was 94%. In 16 @entity0 an early diagnosis could be made when compared with @entity8 . Of the 89 @entity0 11 @entity0 died in hospital. The IMA value was compared between this group and the @entity0 who survived. @entity0 who died had a mean IMA value of 88.5 with a standard deviation of 5.33 whereas in @entity0 who survived the mean value was 78.26 which was not statistically significant. CONCLUSION: In conclusion the benefit of the test would be to rule out @entity6 in @entity0 who present early to @entity2 with inconclusive diagnosis.

title: Role of " XXXX Modified Albumin" (IMA) in @entity6 .

answer: @entity1


abstract: BACKGROUND: Diagnosis of @entity6 ( @entity6 ) is important, due to the associated very high mortality. Failure to diagnose @entity6 is a problem both for the @entity0 and the clinicians. @entity1 modified albumin (IMA) has already been licensed by the US Food and Drug Administration for the diagnosis of suspected @entity5 . METHODS: @entity0 attending the @entity2 ( @entity2 ) within 6  h after having features of @entity6 were selected. IMA was done on admission. Blinded to the IMA results @entity0 were fully evaluated and a diagnosis of non-ischemic @entity4 (NICP), @entity7 ( @entity7 ) or @entity3 ( @entity3 ) was made. Later IMA results were correlated in each group. RESULTS: Mean IMA value was 56.38      23.89  u/ml in NICP group whereas in @entity7 group it was 89.00      7.76  u/ml and @entity3 group was 87.50      9.62  u/ml. This showed a sensitivity of 92% and specificity of 87%. The positive predictive value of the test was 88% and negative predictive value was 94%. In 16 @entity0 an early diagnosis could be made when compared with @entity8 . Of the 89 @entity0 11 @entity0 died in hospital. The IMA value was compared between this group and the @entity0 who survived. @entity0 who died had a mean IMA value of 88.5 with a standard deviation of 5.33 whereas in @entity0 who survived the mean value was 78.26 which was not statistically significant. CONCLUSION: In conclusion the benefit of the test would be to rule out @entity6 in @entity0 who present early to @entity2 with inconclusive diagnosis.

title: Role of " @entity1 Modified Albumin" (IMA) in XXXX .

answer: @entity6


abstract: INTRODUCTION: The impact of @entity1 @entity0 pathways (CPP) on long-term outcome after surgery for @entity2 has not been documented. This study aimed to investigate the effect of CPP on survival in @entity0 who underwent surgery for @entity2 . METHODS: This was a retrospective cohort study performed in a single centre on prospectively collected data from a national database, the Danish @entity2 Group. In total, we reviewed 309 consecutive @entity0 (145 females) with a median age of 70 years (range: 30-92 years), who underwent surgery for @entity2 between 2007 and 2009. RESULTS: A total of 148 @entity0 who underwent elective surgery after the introduction of CPP on 1 April 2008 had a decrease in the median number of days from referral to endoscopy (from 8 to 6, p = 0.001, from referral to oncological treatment (from 46.5 to 32 days, p < 0.001) and from referral to surgery (from 28 to 22 days, p = 0.066), but this latest reduction was not significant. Overall survival (OS) was analysed using the Kaplan Meier method; and variables were compared with the log rank test. The 60-month OS was significantly improved from 61.1% in those who were operated before 1 April 2008 (n = 161) to 72.6% in the CPP group operated after 1 April (p = 0.026). Using the Cox regression model, we found that CPP was an independent factor associated with survival (p = 0.032, hazard ratio = 0.661, 95% confidence interval: 0.454-0.964). CONCLUSION: Introduction of CCPs in a single centre was associated with a significant improvement of overall sur-vival, and using Cox regression we found that the CPP was an independent marker for survival. Larger studies are needed to clearly understand the effect of CPP. FUNDING: not relevant. TRIAL REGISTRATION: not relevant.

title: XXXX pathways are associated with improved long-term survival.

answer: @entity1


abstract: UNASSIGNED: We used two years of eddy covariance (EC) measurements collected over an intensively grazed dairy pasture to better understand the key drivers of changes in soil organic @entity1 stocks. Analysing grazing systems with EC measurements poses significant challenges as the respiration from grazing animals can result in large short-term @entity2 fluxes. As paddocks are grazed only periodically, EC observations derive from a mosaic of paddocks with very different exchange rates. This violates the assumptions implicit in the use of EC methodology. To test whether these challenges could be overcome, and to develop a tool for wider scenario testing, we compared EC measurements with simulation runs with the detailed ecosystem model CenW 4.1. Simulations were run separately for 26 paddocks around the EC tower and coupled to a footprint analysis to estimate net fluxes at the EC tower. Overall, we obtained good agreement between modelled and measured fluxes, especially for the comparison of evapotranspiration rates, with model efficiency of 0.96 for weekly averaged values of the validation data. For net ecosystem productivity (NEP) comparisons, observations were omitted when @entity0 grazed the paddocks immediately around the tower. With those points omitted, model efficiencies for weekly averaged values of the validation data were 0.78, 0.67 and 0.54 for daytime, night-time and 24-hour NEP, respectively. While not included for model parameterisation, simulated gross primary production also agreed closely with values inferred from eddy covariance measurements (model efficiency of 0.84 for weekly averages). The study confirmed that CenW simulations could adequately model @entity1 and water exchange in grazed pastures. It highlighted the critical role of animal respiration for net @entity2 fluxes, and showed that EC studies of grazed pastures need to consider the best approach of accounting for this important flux to avoid unbalanced accounting.

title: Modelling XXXX and water exchange of a grazed pasture in New Zealand constrained by eddy covariance measurements.

answer: @entity1


abstract: BACKGROUND AND OBJECTIVES: @entity5 is a @entity4 inhibitor, used to treat @entity1 ( @entity1 ). Population pharmacokinetic and pharmacodynamic analyses were performed to characterize the impact of clinically relevant intrinsic/extrinsic factors (covariates) on @entity5 exposure and @entity4 inhibition in @entity0 with @entity1 . METHODS: @entity5 plasma concentrations and @entity4 activities were obtained from four studies (two phase 1, two phase 2b). Non-linear mixed-effects modelling techniques were implemented using NONMEM software. The covariates that were studied comprised demographic information and laboratory values, including liver enzyme levels and @entity2 clearance, as well as study-related factors such as @entity3 co-treatment. Covariate effects on parameters describing the pharmacokinetics and pharmacokinetic/pharmacodynamic relationship were investigated using stepwise forward inclusion/backward elimination. RESULTS: The pharmacokinetic analysis included 6,907 measurements of plasma @entity5 concentrations from 462 @entity0 ; the pharmacokinetic/pharmacodynamic analysis included 9,674 measurements of plasma @entity4 activity and @entity5 plasma concentrations from 607 @entity0 . The non-linear pharmacokinetics were described by a target-mediated drug disposition model accounting for the concentration-dependent binding of @entity5 to its target, @entity4 . The difference in exposure between the 5th and 95th percentiles of the covariate distributions and median was <20 % for each single covariate. Likewise, the impact of the covariates on both the half-maximum effect (EC50) and the concentration leading to 80 % @entity4 inhibition was <20 %. CONCLUSION: These analyses show that the investigated factors do not alter the pharmacokinetics and @entity4 inhibitory activity of @entity5 to a clinically relevant extent and that dose adjustment is not necessary on the basis of factors including age, sex and weight.

title: Population Pharmacokinetics and Pharmacodynamics of XXXX in @entity0 with @entity1 .

answer: @entity5


abstract: BACKGROUND AND OBJECTIVES: @entity5 is a @entity4 inhibitor, used to treat @entity1 ( @entity1 ). Population pharmacokinetic and pharmacodynamic analyses were performed to characterize the impact of clinically relevant intrinsic/extrinsic factors (covariates) on @entity5 exposure and @entity4 inhibition in @entity0 with @entity1 . METHODS: @entity5 plasma concentrations and @entity4 activities were obtained from four studies (two phase 1, two phase 2b). Non-linear mixed-effects modelling techniques were implemented using NONMEM software. The covariates that were studied comprised demographic information and laboratory values, including liver enzyme levels and @entity2 clearance, as well as study-related factors such as @entity3 co-treatment. Covariate effects on parameters describing the pharmacokinetics and pharmacokinetic/pharmacodynamic relationship were investigated using stepwise forward inclusion/backward elimination. RESULTS: The pharmacokinetic analysis included 6,907 measurements of plasma @entity5 concentrations from 462 @entity0 ; the pharmacokinetic/pharmacodynamic analysis included 9,674 measurements of plasma @entity4 activity and @entity5 plasma concentrations from 607 @entity0 . The non-linear pharmacokinetics were described by a target-mediated drug disposition model accounting for the concentration-dependent binding of @entity5 to its target, @entity4 . The difference in exposure between the 5th and 95th percentiles of the covariate distributions and median was <20 % for each single covariate. Likewise, the impact of the covariates on both the half-maximum effect (EC50) and the concentration leading to 80 % @entity4 inhibition was <20 %. CONCLUSION: These analyses show that the investigated factors do not alter the pharmacokinetics and @entity4 inhibitory activity of @entity5 to a clinically relevant extent and that dose adjustment is not necessary on the basis of factors including age, sex and weight.

title: Population Pharmacokinetics and Pharmacodynamics of @entity5 in @entity0 with XXXX .

answer: @entity1


abstract: BACKGROUND AND OBJECTIVES: @entity5 is a @entity4 inhibitor, used to treat @entity1 ( @entity1 ). Population pharmacokinetic and pharmacodynamic analyses were performed to characterize the impact of clinically relevant intrinsic/extrinsic factors (covariates) on @entity5 exposure and @entity4 inhibition in @entity0 with @entity1 . METHODS: @entity5 plasma concentrations and @entity4 activities were obtained from four studies (two phase 1, two phase 2b). Non-linear mixed-effects modelling techniques were implemented using NONMEM software. The covariates that were studied comprised demographic information and laboratory values, including liver enzyme levels and @entity2 clearance, as well as study-related factors such as @entity3 co-treatment. Covariate effects on parameters describing the pharmacokinetics and pharmacokinetic/pharmacodynamic relationship were investigated using stepwise forward inclusion/backward elimination. RESULTS: The pharmacokinetic analysis included 6,907 measurements of plasma @entity5 concentrations from 462 @entity0 ; the pharmacokinetic/pharmacodynamic analysis included 9,674 measurements of plasma @entity4 activity and @entity5 plasma concentrations from 607 @entity0 . The non-linear pharmacokinetics were described by a target-mediated drug disposition model accounting for the concentration-dependent binding of @entity5 to its target, @entity4 . The difference in exposure between the 5th and 95th percentiles of the covariate distributions and median was <20 % for each single covariate. Likewise, the impact of the covariates on both the half-maximum effect (EC50) and the concentration leading to 80 % @entity4 inhibition was <20 %. CONCLUSION: These analyses show that the investigated factors do not alter the pharmacokinetics and @entity4 inhibitory activity of @entity5 to a clinically relevant extent and that dose adjustment is not necessary on the basis of factors including age, sex and weight.

title: Population Pharmacokinetics and Pharmacodynamics of @entity5 in XXXX with @entity1 .

answer: @entity0